Thymoma in Myasthenia Gravis : From Diagnosis to Treatment
Author
Source
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-08-10
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
One half of cortical thymoma patients develop myasthenia gravis (MG), while 15% of MG patients have thymomas.
MG is a neuromuscular junction disease caused in 85% of the cases by acetylcholine receptor (AChR) antibodies.
Titin and ryanodine receptor (RyR) antibodies are found in 95% of thymoma MG and 50% of late-onset MG (MG onset ≥50 years), are associated with severe disease, and may predict thymoma MG outcome.
Nonlimb symptom profile at MG onset with bulbar, ocular, neck, and respiratory symptoms should raise the suspicion about the presence of thymoma in MG.
The presence of titin and RyR antibodies in an MG patient younger than 60 years strongly suggests a thymoma, while their absence at any age strongly excludes thymoma.
Thymoma should be removed surgically.
Prethymectomy plasmapheresis/iv-IgG should be considered before thymectomy.
The pharmacological treatment does not differ from nonthymoma MG, except for tacrolimus which is an option in difficult thymoma and nonthymoma MG cases with RyR antibodies.
American Psychological Association (APA)
Romi, Fredrik. 2011. Thymoma in Myasthenia Gravis : From Diagnosis to Treatment. Autoimmune Diseases،Vol. 2011, no. 2011, pp.1-5.
https://search.emarefa.net/detail/BIM-474432
Modern Language Association (MLA)
Romi, Fredrik. Thymoma in Myasthenia Gravis : From Diagnosis to Treatment. Autoimmune Diseases No. 2011 (2011), pp.1-5.
https://search.emarefa.net/detail/BIM-474432
American Medical Association (AMA)
Romi, Fredrik. Thymoma in Myasthenia Gravis : From Diagnosis to Treatment. Autoimmune Diseases. 2011. Vol. 2011, no. 2011, pp.1-5.
https://search.emarefa.net/detail/BIM-474432
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-474432